June, 2016:
Vaxon Biotech publishes article supporting potential of proprietary optimized cryptic peptides as ‘universal neoantigens’
March, 2016: Vaxon Biotech completes enrollment of phase 2b lung cancer trial of first therapeutic vaccine based on optimized cryptic peptides

VAXON Biotech develops innovative immuno-therapeutic products to treat cancer 

VAXON Biotech is a private company, located in Paris – France, that was founded in 2004. The company develops innovative therapeutic vaccines for the treatment of cancers including lung, gastric, prostate, breast, renal, liver and colorectal cancers, using its proprietary technology of optimized cryptic peptides.

Vaxon Biotech’s therapeutic vaccines are intended to treat existing cancers by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. VAXON’s vaccines utilize proprietary optimized cryptic peptides and target universal tumor antigens that are highly overexpressed in a wide range of tumors while being present in very low quantities in normal tissues.

VAXON has a pipeline of tumor vaccines which cover major HLA-I to treat most cancer patients.

The most advanced vaccine, Vx-001, has completed a Phase I/II clinical trial, in which Vx-001 showed favorable tolerance and elicited a strong immune response in most patients, with significant clinical activity in patients with advanced cancers, especially non-small-cell lung cancer (NSCLC), breast cancer and hepatocellular carcinoma (HCC).

Vx-001 is being investigated in a 220-patient, randomized multicentre Phase IIb study in NSCLC, with results expected in 2016.

Vx-001 obtained an orphan medicinal product designation for NSCLC from EMA (European Medicines Agency) in November 2007 and from FDA (Food and Drug Administration, US) in February 2009.